Outcomes of Single Anastomosis Sleeve Jejunal Bypass (SAS-J) VS Sleeve Gastrectomy

Prospective Comparative Study Evaluating the Outcomes of Single Anastomosis Sleeve Jejunal Bypass (SAS-J) VS Sleeve Gastrectomy

The aim of this work is to compare the outcomes of Single Anastomosis Sleeve Jejunal Bypass (SASJ) with sleeve gastrectomy as regards efficacy including sustained weight loss, metabolic syndrome, quality of life, complications and associated comorbidities in morbid obese.

Study Overview

• Status: Completed
• Conditions: Sleeve Gastrectomy; Single Anastomosis Sleeve Jejunal Bypass
• Intervention / Treatment: Procedure: Single anastomosis sleeve jejunal bypass; Procedure: Laparoscopic sleeve gastrectomy

Detailed Description

The most commonly performed bariatric surgery worldwide is the vertical sleeve gastrectomy (VSG), the Roux-en-Y gastric bypass (RYGB), and the One anastomosis (Mini) gastric bypass, which has been demonstrated to produce excellent bariatric and metabolic outcomes.

Single anastomosis sleeve ileal (SASI) bypass was introduced in 2015 as a modification of Santorini's operation in, as it keeps pass to the duodenum so the biliary tree and the whole gut and can be assessed by the endoscope; there are no blind loops, excluded segments or foreign bodies.

• Study Type: Observational
• Enrollment (Actual): 80

Contacts and Locations

Study Locations

• Egypt
  • Cairo, Egypt, 11591
    • Ain Shams University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

This comparative prospective cohort study was conducted in General surgery department, Ain Shams University Hospitals.

Description

Inclusion Criteria:

• Patients age from 18 to 60 years old.
• Both sexes.
• Patients with body mass index (BMI) ≥ 40.
• Patients with BMI (35 - 40) with obesity related comorbidities. (e.g. type 2 diabetes mellitus, obstructive sleep apnea, hypertension, hyperlipidemia, obesity hypoventilation syndrome, non-alcoholic fatty liver disease, gastroesophageal reflux disease and severe arthritis).
• Able to be committed to follow-up.

Exclusion Criteria:

• Patients underwent previous Bariatric surgeries.
• Patients with severe systemic disease, such as congestive heart failure - unstable angina - recent stroke or myocardial infarction less than 3 months ago. Contraindications for insufflation as those with severe cardiovascular or severe restrictive respiratory diseases.
• Patients that refused to participate in the study.
• Patients with psychiatric illness.
• Preoperative upper GI endoscopy findings of GERD class C and Barrett's oesophagus
• Previous upper GIT surgery or liver cirrhosis.
• Patients on oral steroid therapy.
• Not fit for general anaesthesia (e.g. patients with severe heart disease or untreatable coagulopathies).
• Significant abdominal adhesions.
• Major psychiatric illness.
• Pregnant patients.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Group (A) (SASJ Group); Patients underwent single anastomosis sleeve jejunal bypass as a metabolic and weight loss surgery.	Procedure: Single anastomosis sleeve jejunal bypass; Patients underwent single anastomosis sleeve jejunal bypass as a metabolic and weight loss surgery.
Group (B) (Lap Gastric Sleeve Group); Patients underwent laparoscopic sleeve gastrectomy(LGS) as a metabolic and weight loss surgery.	Procedure: Laparoscopic sleeve gastrectomy; Patients underwent laparoscopic sleeve gastrectomy (LGS) as a metabolic and weight loss surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Weight loss	Weight loss was recorded.	1 month after the procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Metabolic syndrome	Metabolic syndrome was recorded.	1 month after the procedure
Assessment of quality of life	quality of life was assessed using specific scoring system is a variation of the BAROS (Bariatric Analysis and Reporting Outcome System). The specific tiers you listed (High, Moderate, and Mild Improvement); High Improvement excess Weight Loss (%EWL) >50% + comorbidity resolution + no complications.; Moderate Improvement EWL 30-50% + partial comorbidity resolution.; Mild Improvement EWL <30% + no major issues.	1 month after the procedure
Incidence of complications	Incidence of complications such as gastroesophageal reflux disease (GERD), bile reflux, gall stones, reoperations, and postoperative bleeding were recorded.	1 month after the procedure

Collaborators and Investigators

• Sponsor: Ain Shams University

Study record dates

Study Major Dates

• Study Start (Actual): August 15, 2023
• Primary Completion (Actual): August 1, 2025
• Study Completion (Actual): August 1, 2025

Study Registration Dates

• First Submitted: February 10, 2026
• First Submitted That Met QC Criteria: February 10, 2026
• First Posted (Actual): February 17, 2026

Study Record Updates

• Last Update Posted (Actual): February 17, 2026
• Last Update Submitted That Met QC Criteria: February 10, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: 13/8/2023.

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
• IPD Sharing Time Frame: After the end of study for one year.
• IPD Sharing Access Criteria: The data will be available upon a reasonable request from the corresponding author.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No